Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.64 |
| ▸ | CNR1 | P21554 | 2/20 | 0.63 |
| ▸ | FPR1 | P21462 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.51 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | KLK7 | P49862 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18262740 | 0.88 | FPR2 (0.74) | FPR2CNR1FPR1PKMUTS2R | |
| SCHEMBL20397782 | 0.88 | FPR2 (0.74) | FPR2CNR1FPR1PKMUTS2R | |
| SCHEMBL18262738 | 0.88 | FPR2 (0.74) | FPR2CNR1FPR1PKMUTS2R | |
| SCHEMBL20415806 | 0.81 | PKM (0.68) | FPR2FPR1PKMSAE1UBA2 | |
| SCHEMBL15925980 | 0.81 | PKM (0.72) | FPR2PKMUTS2RSAE1UBA2 | |
| SCHEMBL22753565 | 0.80 | FPR2 (0.68) | FPR2CNR1FPR1PKMUTS2R | |
| SCHEMBL3075693 | 0.79 | PKM (0.86) | FPR2PKMSAE1UBA2KMT2A | |
| SCHEMBL20415839 | 0.78 | CNR1 (0.64) | FPR2CNR1FPR1PKMUTS2R | |
| SCHEMBL22723032 | 0.78 | FPR2 (0.65) | FPR2CNR1FPR1PKMUTS2R | |
| SCHEMBL16562291 | 0.78 | CNR1 (1.00) | FPR2CNR1NPC1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, SAAL1, FPR2 | FPR2 3/4885CNR1 338/4885FPR1 1/4885 |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, SAAL1 | FPR2 2/4885CNR1 318/4885FPR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.